Huisheng Biotech (300871.SZ): Net profit is expected to drop 52.57% to 63% year-on-year in 2023

On April 10, Gelonghui | Huisheng Biotech (300871.SZ) announced that it expects net profit of 19.5 million yuan to 25 million yuan in 2023, down 52.57% to 63% from the same period last year, after deducting non-net loss of 8.5 million yuan to 13 million yuan. In the early stages, the company did not accrue individual credit impairment losses on accounts receivable from individual customers based on a comprehensive assessment of factors such as customer repayment conditions, financial changes, and development trends in the pig breeding industry. Due to the company's recent acquisition of new information, the customer showed signs of business risk and intended to apply to the court for restructuring and pre-restructuring

Gelonghui FinanceApr 10 07:47 ET

Huisheng Biotech (300871.SZ) plans to raise no more than 250 million yuan in capital from enterprises controlled by actual controllers, with an issue price of 9.57 yuan/share

Huisheng Biotech (300871.SZ) disclosed plans to issue A-shares to specific targets in 2024. This issuance...

Zhitong FinanceApr 3 10:04 ET

Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) 30% Jump Shows Its Popularity With Investors

Hvsen Biotechnology Co., Ltd. (SZSE:300871) shareholders are no doubt pleased to see that the share price has bounced 30% in the last month, although it is still struggling to make up recently lost gr

Simply Wall StMar 20 18:04 ET

Huisheng Biotech (300871.SZ): 2023 Employee Stock Ownership Plan Non-transactional Transfer Completed

Gelonghui, Feb. 8, 丨 Huisheng Biotech (300871.SZ) announced that on February 7, 2024, the company received a “Securities Transfer Registration Confirmation” issued by the Shenzhen branch of China Securities Registration and Settlement Co., Ltd., and 1,635,450 shares of the company's shares held by the “Wuhan Huisheng Biotechnology Co., Ltd. Repurchase Special Securities Account” were transferred to “Wuhan Huisheng Biotechnology Co., Ltd. - 2023 Employee Stock Ownership Plan” on February 6, 2024. The number of shares transferred accounts for 0.99% of the company's total share capital. 10.00 yuan/share. All companies

Gelonghui FinanceFeb 8 06:09 ET

Huisheng Biotech (300871.SZ): Proposed 2023 employee shareholding plan, the total amount raised will not exceed 167.385 million yuan

Gelonghui, December 27丨Huisheng Biotech (300871.SZ) announced the 2023 employee shareholding plan (draft). The total amount of capital to be raised in the employee shareholding plan is not more than RMB 16.7385 million. Using “shares” as the subscription unit, each share is 1.00 yuan. The maximum number of shares in the employee shareholding plan is 16.7385 million shares. After review and approval by the company's shareholders' meeting, the employee's shareholding plan will use 10 yuan/share to repurchase the shares already repurchased by the company's special securities account. The participants in this employee stock ownership plan are company directors (excluding independent directors), supervisors, and senior management.

Gelonghui FinanceDec 27, 2023 06:01 ET

Huisheng Biology (300871.SZ): The tylosin project with an annual output of 1,000 tons, the tylosin production line expansion project with an annual output of 1,000 tons, and the tyomycin production line expansion project with an annual output of 600 tons

Glonghui October 30 | Huisheng Biotech (300871.SZ) held an investor relations event on October 29, 2023, on “How is the company's raw material project progressing?” The company replied that the company's tylosin project with an annual output of 1,000 tons, an annual tylosin production line expansion project with an annual output of 1,000 tons, and a tyomycin production line expansion project with an annual output of 600 tons have been fully completed and put into operation. Currently, through continuous optimization of strains and process improvements, tylosin production costs are gradually trending towards the industry average. As capacity utilization increases to create scale effects and further optimization of strains and processes, API projects are imminent

Gelonghui FinanceOct 30, 2023 02:51 ET